Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
146 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Cancer Pain - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Cancer Pain - Pipeline Review, H2 2014', provides an overview of the Cancer Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cancer Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cancer Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cancer Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Cancer Pain Overview 11 Therapeutics Development 12 Pipeline Products for Cancer Pain - Overview 12 Pipeline Products for Cancer Pain - Comparative Analysis 13 Cancer Pain - Therapeutics under Development by Companies 14 Cancer Pain - Therapeutics under Investigation by Universities/Institutes 17 Cancer Pain - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Cancer Pain - Products under Development by Companies 21 Cancer Pain - Products under Investigation by Universities/Institutes 23 Cancer Pain - Companies Involved in Therapeutics Development 24 Amgen Inc. 24 AstraZeneca PLC 25 BioDelivery Sciences International, Inc. 26 Nektar Therapeutics 27 Daiichi Sankyo Company, Limited 28 Egalet Corporation 29 Aphios Corporation 30 Nippon Kayaku Co., Ltd. 31 Nippon Shinyaku Co., Ltd. 32 Orion Oyj 33 Pfizer Inc. 34 Zeria Pharmaceutical Co Ltd 35 GW Pharmaceuticals plc 36 IntelGenx Corp. 37 Benitec Biopharma Limited 38 Kolon Life Science, Inc. 39 Teikoku Seiyaku Co., Ltd. 40 Aoxing Pharmaceutical Company, Inc 41 BCN Peptides, S.A. 42 Grunenthal GmbH 43 AngioChem Inc. 44 WEX Pharmaceuticals Inc. 45 Virobay Inc. 46 Dimerix Bioscience Pty Ltd 47 Winston Pharmaceuticals, Inc. 48 Encore Therapeutics Inc. 49 Sorrento Therapeutics, Inc. 50 Afferent Pharmaceuticals, Inc. 51 ChironWells GmbH 52 Northern Light Pharmaceuticals AB 53 Cancer Pain - Therapeutics Assessment 54 Assessment by Monotherapy Products 54 Assessment by Target 55 Assessment by Mechanism of Action 59 Assessment by Route of Administration 63 Assessment by Molecule Type 65 Drug Profiles 67 fentanyl citrate - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 tramadol hydrochloride SR - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 tilidine hydrochloride - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 nabiximols - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Tetrodotoxin - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 cebranopadol - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 morphine sulfate ER - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 TK-641 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 tapentadol hydrochloride ER - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 methadone hydrochloride - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 hydromorphone hydrochloride - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 tanezumab - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 saracatinib - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 fulranumab - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 dexmedetomidine hydrochloride - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 fentanyl citrate - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 PGN-202 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 fentanyl citrate SR - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 resiniferatoxin - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 DD-04107 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 dronabinol - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 VBY-825 - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 zucapsaicin - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 ANG-2002 - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 Z-360 - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 Nervarna - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 NKTR-192 - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 buprenorphine hydrochloride ER - Drug Profile 107 Product Description 107 Mechanism of Action 107 R&D Progress 107 AF-353 - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 INT-0028 - Drug Profile 109 Product Description 109 Mechanism of Action 109 R&D Progress 109 HS-198 - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 QX-314 - Drug Profile 111 Product Description 111 Mechanism of Action 111 R&D Progress 111 calpastatin - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 Small Molecule to Antagonize Chemokine Receptor for Cancer Pain - Drug Profile 113 Product Description 113 Mechanism of Action 113 R&D Progress 113 KLS-2010 - Drug Profile 114 Product Description 114 Mechanism of Action 114 R&D Progress 114 ZEP-3 - Drug Profile 115 Product Description 115 Mechanism of Action 115 R&D Progress 115 Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain - Drug Profile 117 Product Description 117 Mechanism of Action 117 R&D Progress 117 BBI-11008 - Drug Profile 118 Product Description 118 Mechanism of Action 118 R&D Progress 118 Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 119 Product Description 119 Mechanism of Action 119 R&D Progress 119 Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 120 Product Description 120 Mechanism of Action 120 R&D Progress 120 Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 121 Product Description 121 Mechanism of Action 121 R&D Progress 121 ketamine hydrochloride ER - Drug Profile 122 Product Description 122 Mechanism of Action 122 R&D Progress 122 DMX-200 - Drug Profile 123 Product Description 123 Mechanism of Action 123 R&D Progress 123 Cancer Pain - Recent Pipeline Updates 124 Cancer Pain - Dormant Projects 137 Cancer Pain - Discontinued Products 138 Cancer Pain - Product Development Milestones 139 Featured News & Press Releases 139 Sep 10, 2014: Cyclacel Announces Abstract Selected for Presentation at Society of Hematologic Oncology Annual Meeting 139 Sep 03, 2014: Rexahn Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Novel Targeted Cancer Drug Delivery Platform 139 Aug 26, 2014: Pfizer And Merck To Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen 139 Jul 16, 2014: Prima Receives US Patent Grant for CVac 141 Apr 28, 2014: Hospira Files Petition Against Aurobindo Over Patent Infringement 142 Apr 28, 2014: GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain 142 Feb 18, 2014: Preclinical Data on Angiochem Pain Program Published in Journal of Clinical Investigation 143 Feb 10, 2014: Sorrento Therapeutics Expands its Exclusive Rights to Cynviloq to Include Australia, Canada and Mexico 143 Dec 05, 2013: Orion settles patent dispute over the proprietary drug Precedex 144 Jul 29, 2013: BioDelivery Sciences Announces Regulatory Approval of ONSOLIS in Taiwan 144 Appendix 145 Methodology 145 Coverage 145 Secondary Research 145 Primary Research 145 Expert Panel Validation 145 Contact Us 146 Disclaimer 146
List of Tables Number of Products under Development for Cancer Pain, H2 2014 12 Number of Products under Development for Cancer Pain - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 15 Number of Products under Investigation by Universities/Institutes, H2 2014 17 Comparative Analysis by Late Stage Development, H2 2014 18 Comparative Analysis by Clinical Stage Development, H2 2014 19 Comparative Analysis by Early Stage Development, H2 2014 20 Products under Development by Companies, H2 2014 21 Products under Investigation by Universities/Institutes, H2 2014 23 Cancer Pain - Pipeline by Amgen Inc., H2 2014 24 Cancer Pain - Pipeline by AstraZeneca PLC, H2 2014 25 Cancer Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2014 26 Cancer Pain - Pipeline by Nektar Therapeutics, H2 2014 27 Cancer Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 28 Cancer Pain - Pipeline by Egalet Corporation, H2 2014 29 Cancer Pain - Pipeline by Aphios Corporation, H2 2014 30 Cancer Pain - Pipeline by Nippon Kayaku Co., Ltd., H2 2014 31 Cancer Pain - Pipeline by Nippon Shinyaku Co., Ltd., H2 2014 32 Cancer Pain - Pipeline by Orion Oyj, H2 2014 33 Cancer Pain - Pipeline by Pfizer Inc., H2 2014 34 Cancer Pain - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2014 35 Cancer Pain - Pipeline by GW Pharmaceuticals plc, H2 2014 36 Cancer Pain - Pipeline by IntelGenx Corp., H2 2014 37 Cancer Pain - Pipeline by Benitec Biopharma Limited, H2 2014 38 Cancer Pain - Pipeline by Kolon Life Science, Inc., H2 2014 39 Cancer Pain - Pipeline by Teikoku Seiyaku Co., Ltd., H2 2014 40 Cancer Pain - Pipeline by Aoxing Pharmaceutical Company, Inc, H2 2014 41 Cancer Pain - Pipeline by BCN Peptides, S.A., H2 2014 42 Cancer Pain - Pipeline by Grunenthal GmbH, H2 2014 43 Cancer Pain - Pipeline by AngioChem Inc., H2 2014 44 Cancer Pain - Pipeline by WEX Pharmaceuticals Inc., H2 2014 45 Cancer Pain - Pipeline by Virobay Inc., H2 2014 46 Cancer Pain - Pipeline by Dimerix Bioscience Pty Ltd, H2 2014 47 Cancer Pain - Pipeline by Winston Pharmaceuticals, Inc., H2 2014 48 Cancer Pain - Pipeline by Encore Therapeutics Inc., H2 2014 49 Cancer Pain - Pipeline by Sorrento Therapeutics, Inc., H2 2014 50 Cancer Pain - Pipeline by Afferent Pharmaceuticals, Inc., H2 2014 51 Cancer Pain - Pipeline by ChironWells GmbH, H2 2014 52 Cancer Pain - Pipeline by Northern Light Pharmaceuticals AB, H2 2014 53 Assessment by Monotherapy Products, H2 2014 54 Number of Products by Stage and Target, H2 2014 57 Number of Products by Stage and Mechanism of Action, H2 2014 61 Number of Products by Stage and Route of Administration, H2 2014 64 Number of Products by Stage and Molecule Type, H2 2014 66 Cancer Pain Therapeutics - Recent Pipeline Updates, H2 2014 124 Cancer Pain - Dormant Projects, H2 2014 137 Cancer Pain - Discontinued Products, H2 2014 138
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.